38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase…
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial…
-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline…
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease…
SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75$4.5 Million Bridge Financing led by North South VenturesComposition…
Represents first sales by the Company into an ambulatory surgery center Follows successful evaluation by Island Ambulatory Surgery Center’s founder…
- Company Now Focused on Proprietary Drug-Eluting Biomatrix Platform - SILVER SPRING, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Elutia…
One-Year Outcomes Published in JSCAI Confirm Excellent, Consistent IVL Safety and Effectiveness Across SexesSANTA CLARA, Calif., Nov. 09, 2023 (GLOBE…
Demonstrated that P2B001 provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep–related and…
SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of…